SCIEX and Intabio signed an agreement to couple Intabio’s Blaze™ system with SCIEX high resolution accurate mass (HRAM) systems. This collaboration is geared to accelerate and transform biotherapeutic development and biomanufacturing, according to officials at both companies.

The integration between Blaze and SCIEX HRAM systems provides imaged capillary isoelectric focusing with mass spectrometry (iCIEF-MS) in order to simultaneously characterize and identify intact protein charge variants. The successful integration of iCIEF-MS workflows will streamline current laborious and time-consuming approaches in the biopharma environment to identify, monitor and characterize critical quality attributes in intact protein samples for the development and manufacture of next-gen therapeutics, said Lena Wu, PhD, Intabio CEO and co-founder.

“By coupling iCIEF separations directly to leading high resolution MS systems, the Blaze system eliminates a serious laboratory bottleneck for drug developers,” she explained. “Blaze integration with SCIEX flagship MS platforms will enable biopharma to accelerate critical decisions and ultimately reduce development timelines.”

The commercial release of the Blaze system is scheduled for Q4 of 2020 and the integrated iCIEF-MS workflow will be available on SCIEX TripleTOF® 6600+ Systems.

“This work demonstrates our continued commitment to collaborate with key innovators to develop practical solutions for our biopharmaceutical customers,” said Mani Krishnan, VP of global biopharma and capillary electrophoresis at SCIEX. “Providing analytical workflows around iCIEF-MS will assist in solving some of the key challenges faced by the industry.”

The post SCIEX and Intabio Collaborate to Accelerate Drug Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Source